Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been registered by the TGA for the treatment of Australian adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a)
- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299
Press Releases - Specialised Therapeutics
April 20, 2026
New Combination Therapy for Advanced Small Cell Lung Cancer Approved in Australia and Singapore
Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), as a new first-line maintenance treatment option for adult patients in Australia and Singapore, who have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer.
February 10, 2026
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
Eligible women with breast cancer in Thailand now have access to a new therapy, NERLYNX® (neratinib), for the first time. The launch of NERLYNX provides an important new treatment option for women diagnosed with human epidermal growth factor receptor 2 positive (HER2+) breast cancer. This follows the approval of NERLYNX by the Thai FDA in December 2024 as a single agent for the treatment of early-stage HER2+ breast cancer, and in combination with capecitabine for the treatment of advanced or metastatic HER2+ breast cancer.
June 13, 2025
Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
Singapore 11 June 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add
May 30, 2025
New Therapy for Children with Growth Hormone Deficiency Approved in Australia
SKYTROFA® ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.1 Singapore 30 May 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new once-weekly injectable therapy for paediatric growth hormone deficiency (GHD).2 The Therapeutic Goods
February 21, 2025
First and Only Treatment for Chronic Hypoparathyroidism Approved in Australia
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval Singapore 21 February 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by
January 8, 2024
Specialised Therapeutics Signs Exclusive Agreement with Ascendis Pharma A/S for Distribution and Commercialisation of Three Endocrinology Therapies in Australia and Select South-East Asia Countries
Agreement between Ascendis Pharma A/S and ST is for the exclusive distribution and commercialisation of three Ascendis Pharma endocrinology therapies Two of the therapies are already internationally approved, the third is in development following successful Phase 2 data ST’s exclusive distribution agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore 8 January
October 13, 2023
Specialised Therapeutics Signs Exclusive License Agreement with CanariaBio for New Ovarian Cancer Therapy
First ovarian cancer therapy for ST oncology portfolio Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 Phase 3 results expected in 2025 Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore and Seoul, South Korea, 13 October 2023: Independent
September 8, 2023
World Orphan Drug Alliance Welcomes Specialised Therapeutics
SEA’s largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA) World Orphan Drug Alliance (WODA) now spans 152 countries. WODA offers a ‘one-stop’ solution for biotech companies
August 28, 2023
Specialised Therapeutics Acquires Commercialisation Rights to New Oral MND Therapy
Singapore and Tilburg, Netherlands, August 28 2023: Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis (ALS) – the most common form of Motor Neurone Disease (MND) – in Australia and New Zealand. The therapy is